Kestra Medical Technologies, Ltd. (KMTS)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Kestra Medical Technologies, Ltd. (KMTS) Q2 2026 Earnings Call Transcript
Kestra Medical Technologies, Ltd. (KMTS) Q2 2026 Earnings Call Transcript
Kestra Medical Technologies, Ltd. (KMTS) Q1 2026 Earnings Call Transcript
Kestra Medical Technologies, Ltd. (NASDAQ:KMTS ) Q1 2026 Earnings Call September 11, 2025 4:30 PM EDT Company Participants Neil Bhalodkar - Vice President of Investor Relations Brian Webster - Founder, President, CEO & Director Vaseem Mahboob - Chief Financial Officer Conference Call Participants Travis Steed - BofA Securities, Research Division Frederick Wise - Stifel, Nicolaus & Company, Incorporated, Research Division Matthew O'Brien - Piper Sandler & Co., Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Michael Polark - Wolfe Research, LLC Presentation Operator Good afternoon, and welcome to the Kestra Medical Technologies Earnings Conference Call.
Kestra Medical: Skipping A Heartbeat
Kestra Medical Technologies, Ltd. shows strong sales growth but faces significant operating losses and a concerning slowdown in sequential revenue growth. Despite a large addressable market and innovative cardiac device, the company's one-product focus and high valuation amplify risks. Recent quarters reveal only modest revenue increases, casting doubt on the sustainability of Kestra's growth trajectory post-IPO.
Kestra Medical Technologies: A Potential Promising Public Offering
Kestra Medical Technologies has seen rapid growth but incurs substantial operating losses, making its valuation exercise a hard one. The company's Cardiac Recovery System, including the ASSURE WCD, addresses a significant market need for sudden cardiac arrest intervention. Despite strong product adoption and a large addressable market, risks include high losses, being a one-product business, and potential growth slowdown.
Kestra Medical Technologies aims to raise $150M in IPO
Kirkland, Wash.-based Kestra Medical Technologies is aiming to raise about $150 million in its initial public offering, pricing shares between $14 and $16 on the Nasdaq, according to a new regulatory filing.
Kestra Medical Files For IPO On Substantial Operating Losses
Kestra Medical Technologies, Ltd. is experiencing strong revenue growth but faces high operating losses and significant cash burn. The firm markets a wearable cardiac defibrillator, ASSURE WCD, with a lease business model, showing promising efficacy but dependent on reimbursement policies. The global cardiac arrest treatment market is projected to grow significantly, presenting opportunities for Kestra despite competition and regulatory risks.
